Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Bergh

Showing results (211-220 of 233) with videos related to

Pageof 24
Sort By:
European Journal of Cancer (Oxford, England : 1990)|January 1, 2000
Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast GroupJ Sjöström, C Blomqvist, H Mouridsen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2000
Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancerJ Sjöström, C Blomqvist, P Heikkilä, et al.
European Journal of Cancer (Oxford, England : 1990)|March 2, 2002
C-erbB-2 expression does not predict response to docetaxel or sequential methotrexate and 5-fluorouracil in advanced breast cancerJ Sjöström, J Collan, K von Boguslawski, et al.
Breast Cancer Research and Treatment|June 6, 2013
Serum thymidine kinase activity compared with CA 15-3 in locally advanced and metastatic breast cancer within a randomized trialJ Bjöhle, J Bergqvist, J S Gronowitz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 11, 2016
Research needs in breast cancerF Cardoso, N Harbeck, C H Barrios, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 26, 2012
Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifenA Prat, J S Parker, C Fan, et al.
Lancet (London, England)|December 14, 2011
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials, R Peto, C Davies, et al.
Breast (Edinburgh, Scotland)|October 11, 2011
Triple negative breast cancer: proposals for a pragmatic definition and implications for patient management and trial designW Eiermann, J Bergh, F Cardoso, et al.
Acta Oncologica (Stockholm, Sweden)|July 10, 2001
The Swedish Council on Technology Assessment in Health Care (SBU) systematic overview of chemotherapy effects in some major tumour types--summary and conclusionsB Glimelius, J Bergh, L Brandt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 16, 2007
Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapyN Wilking, E Lidbrink, T Wiklund, et al.
Pageof 24

Showing results (211-220 of 233) with videos related to

Sort By:
Pageof 24
European Journal of Cancer (Oxford, England : 1990)|January 1, 2000
Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast GroupJ Sjöström, C Blomqvist, H Mouridsen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2000
Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancerJ Sjöström, C Blomqvist, P Heikkilä, et al.
European Journal of Cancer (Oxford, England : 1990)|March 2, 2002
C-erbB-2 expression does not predict response to docetaxel or sequential methotrexate and 5-fluorouracil in advanced breast cancerJ Sjöström, J Collan, K von Boguslawski, et al.
Breast Cancer Research and Treatment|June 6, 2013
Serum thymidine kinase activity compared with CA 15-3 in locally advanced and metastatic breast cancer within a randomized trialJ Bjöhle, J Bergqvist, J S Gronowitz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 11, 2016
Research needs in breast cancerF Cardoso, N Harbeck, C H Barrios, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 26, 2012
Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifenA Prat, J S Parker, C Fan, et al.
Lancet (London, England)|December 14, 2011
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials, R Peto, C Davies, et al.
Breast (Edinburgh, Scotland)|October 11, 2011
Triple negative breast cancer: proposals for a pragmatic definition and implications for patient management and trial designW Eiermann, J Bergh, F Cardoso, et al.
Acta Oncologica (Stockholm, Sweden)|July 10, 2001
The Swedish Council on Technology Assessment in Health Care (SBU) systematic overview of chemotherapy effects in some major tumour types--summary and conclusionsB Glimelius, J Bergh, L Brandt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 16, 2007
Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapyN Wilking, E Lidbrink, T Wiklund, et al.
Pageof 24